How to Help Your Patients Save Money on AirDuo: A Provider's Guide to Savings Programs

The discontinuation of AirDuo RespiClick in July 2025 has forced many asthma patients to navigate a changed landscape for their maintenance inhaler — and medication cost is often a central concern. As a prescriber, you are uniquely positioned to guide patients toward the most cost-effective therapeutic path. This guide summarizes the key savings programs available for fluticasone/salmeterol and equivalent ICS/LABA inhalers in 2026, and how to incorporate cost into your prescribing decisions.

Why Cost-Aware Prescribing Matters for ICS/LABA Inhalers

Non-adherence due to cost is a well-documented problem in asthma management. Patients who can't afford their maintenance inhaler don't take it — leading to more rescue inhaler use, more urgent care visits, and more hospitalizations. The economic burden falls on patients and the healthcare system alike. When you take 5 minutes to identify the most affordable covered option for a patient, you may be preventing an ER visit.

The landscape for fluticasone/salmeterol savings in 2026:

• The AirDuo RespiClick brand is discontinued — its former manufacturer savings card is no longer active.
• The authorized generic (fluticasone/salmeterol MDPI) costs $100–165 at retail cash price.
• Discount cards can reduce cash prices to $55–72 per inhaler.
• Equivalent drugs (Wixela Inhub, Advair) have robust savings programs worth considering for cost-motivated switches.

Savings Option 1: Authorized Generic + Discount Cards (Best for Uninsured/High-Deductible Patients)

For patients without insurance or on high-deductible plans, the lowest-cost approach is:

1. Prescribe the authorized generic (Fluticasone Propionate/Salmeterol MDPI, any strength, DAW-0).
2. Direct the patient to compare GoodRx, SingleCare, and WellRx prices for their specific strength and pharmacy — prices can vary by $40–60 between pharmacies.
3. GoodRx coupons can bring the price to as low as $55–72 per inhaler vs. retail of $100–165.

Savings Option 2: Wixela Inhub Savings Card (Best for Commercially Insured Patients)

For commercially insured patients, the Wixela Inhub savings program offers outstanding value:

• $10 per 30-day prescription with savings of up to $50 per fill
• Up to 12 monthly fills per year — maximum $600 in annual savings
• Wixela Inhub contains fluticasone propionate/salmeterol in a Diskus-style inhaler (same active ingredients, different device)
• Important: Dose conversion is required — AirDuo 55/14 ≈ Wixela 100/50; AirDuo 113/14 ≈ Wixela 250/50; AirDuo 232/14 ≈ Wixela 500/50. Patients need technique re-education for the Diskus device.

Not eligible: Medicare and Medicaid patients cannot use manufacturer savings cards.

Savings Option 3: Advair $35 Monthly Cap (GSK, Commercially Insured)

Since January 2025, GSK has capped Advair Diskus and Advair HFA out-of-pocket costs at $35 per month for eligible commercially insured patients. Advair contains the same active ingredients (fluticasone propionate/salmeterol) as AirDuo. The Diskus and HFA inhalers use different devices, requiring patient re-education.

Savings Option 4: Insurance Formulary Optimization

Before prescribing any ICS/LABA inhaler, run a formulary check through your EHR or call your practice's pharmacy navigator. In 2026:

• Generic fluticasone/salmeterol MDPI (AirDuo authorized generic) is typically Tier 1–2 on most commercial and Medicare Part D plans
• Some plans may prefer Wixela Inhub or other fluticasone/salmeterol Diskus generics
• Symbicort generic (budesonide/formoterol) is increasingly covered at Tier 1 as generic versions roll out

When switching a patient to save money, always verify clinical appropriateness alongside the formulary tier. A $15 copay doesn't help if the patient's asthma worsens on a different regimen.

Savings Option 5: Patient Assistance Programs (PAPs) for Low-Income/Uninsured Patients

Teva offers patient assistance programs for qualifying patients. Eligibility is typically based on income relative to the federal poverty level. Your office's social worker or care coordinator can help patients apply. Useful resources:

• NeedyMeds.org — comprehensive PAP database searchable by drug
• RxAssist.org — updated PAP resource for healthcare providers
• Partnership for Prescription Assistance (PPA) — multi-manufacturer PAP hub

Cost Decision Framework for Providers

Use this quick framework to guide cost-saving prescribing decisions:

• Commercially insured: Run formulary check → generic fluticasone/salmeterol MDPI or Diskus → savings card (Wixela $10/mo or Advair $35 cap)
• Medicare Part D: Check plan formulary → generic fluticasone/salmeterol MDPI likely Tier 1–2 → cash + GoodRx if copay is higher
• Uninsured/cash-pay: Generic MDPI + GoodRx (~$55–72) OR check PAP eligibility → Teva assistance
• Low income/uninsured: Patient assistance program via NeedyMeds.org or RxAssist.org

For patients who are having trouble locating their inhaler in addition to cost challenges, medfinder for providers is a referral resource for checking pharmacy stock. See also our provider guide to helping patients find AirDuo in stock.